Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Sebban

Showing results (121-130 of 145) with videos related to

Pageof 15
Sort By:
Blood|March 25, 2000
Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the groupe d'études des lymphomes de l'Adulte H89 trialC Fermé, C Sebban, C Hennequin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study GroupI Ray-Coquard, A Le Cesne, M T Rubio, et al.
European Journal of Cancer (Oxford, England : 1990)|September 6, 2003
Evaluation of core needle biopsy as a substitute to open biopsy in the diagnosis of soft-tissue massesI Ray-Coquard, D Ranchère-Vince, P Thiesse, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2012
A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study)C Sebban, A Lefranc, L Perrier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1997
Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 yearsY Bastion, J Y Blay, M Divine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1997
Follicular large-cell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. Groupe d'Etude des Lymphomes de l'AdulteD Wendum, C Sebban, P Gaulard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2000
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte studyC Haioun, E Lepage, C Gisselbrecht, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 11, 1998
S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidolM J Millan, R Schreiber, A Dekeyne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trialC Guglielmi, F Gomez, T Philip, et al.
Leukemia|September 26, 1997
Age-adapted induction treatment of acute lymphoblastic leukemia in the elderly and assessment of maintenance with interferon combined with chemotherapy. A multicentric prospective study in forty patients. French Group for Treatment of Adult Acute Lymphoblastic LeukemiaA Delannoy, C Sebban, P Cony-Makhoul, et al.
Pageof 15

Showing results (121-130 of 145) with videos related to

Sort By:
Pageof 15
Blood|March 25, 2000
Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the groupe d'études des lymphomes de l'Adulte H89 trialC Fermé, C Sebban, C Hennequin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study GroupI Ray-Coquard, A Le Cesne, M T Rubio, et al.
European Journal of Cancer (Oxford, England : 1990)|September 6, 2003
Evaluation of core needle biopsy as a substitute to open biopsy in the diagnosis of soft-tissue massesI Ray-Coquard, D Ranchère-Vince, P Thiesse, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2012
A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study)C Sebban, A Lefranc, L Perrier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1997
Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 yearsY Bastion, J Y Blay, M Divine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1997
Follicular large-cell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. Groupe d'Etude des Lymphomes de l'AdulteD Wendum, C Sebban, P Gaulard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2000
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte studyC Haioun, E Lepage, C Gisselbrecht, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 11, 1998
S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidolM J Millan, R Schreiber, A Dekeyne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trialC Guglielmi, F Gomez, T Philip, et al.
Leukemia|September 26, 1997
Age-adapted induction treatment of acute lymphoblastic leukemia in the elderly and assessment of maintenance with interferon combined with chemotherapy. A multicentric prospective study in forty patients. French Group for Treatment of Adult Acute Lymphoblastic LeukemiaA Delannoy, C Sebban, P Cony-Makhoul, et al.
Pageof 15